Recent News

• 10.20.2026 - Penumbra’s CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)
• 10.12.2026 - Young, Healthy, and at Risk: These Patient Stories Show Blood Clots Don’t Discriminate
• 10.07.2026 - CIRSE 2026: New STRIKE-PE Analysis Shows Sustained Improvements in Functional Outcomes and Quality of Life One Year After CAVT Treatment
• 10.06.2026 - New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism
• 09.25.2026 - A Patient Was Told Her Pelvic Pain Was “Normal” for Years. It Wasn’t.
• 09.23.2026 - Employee Spotlight: Dillon Gedeon
• 09.21.2026 - What Should Physicians Expect from the Next Generation of Mechanical Thrombectomy Technology?
• 09.10.2026 - How Complete Clot Ingestion May Reshape Aspiration Thrombectomy: Early Insights from THUNDER Investigators
• 09.09.2026 - Penumbra Launches Link, Expanding Vascular Thrombectomy Options for Physicians
• 08.25.2026 - Employee Spotlight: Olina Islam

Recent Filings

• 10.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.19.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.13.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 07.30.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.30.2026 - 8-K Current report
• 07.30.2026 - EX-99.1 EX-99.1
• 06.22.2026 - 8-K Current report
• 05.29.2026 - SD Specialized disclosure report
• 05.21.2026 - 4 Statement of changes in beneficial ownership of securities